Capillary hemodynamics and contracting skeletal muscle oxygen pressures in male rats with heart failure: Impact of soluble guanylyl cyclase activator

In heart failure with reduced ejection fraction (HFrEF), nitric oxide-soluble guanylyl cyclase (sGC) pathway dysfunction impairs skeletal muscle arteriolar vasodilation and thus capillary hemodynamics, contributing to impaired oxygen uptake (VO2) kinetics. Targeting this pathway with sGC activators offers a new treatment approach to HFrEF. We tested the hypotheses that sGC activator administration would increase the O2 delivery (QO2)-to-VO2 ratio in the skeletal muscle interstitial space (PO2is) of HFrEF rats during twitch contractions due, in part, to increases in red blood cell (RBC) flux (fRBC), velocity (VRBC), and capillary hematocrit (Hctcap). HFrEF was induced in male Sprague-Dawley rats via myocardial infarction. After 3 weeks, rats were treated with 0.3 mg/kg of the sGC activator BAY 60-2770 (HFrEF + BAY; n = 11) or solvent (HFrEF; n = 9) via gavage b.i.d for 5 days prior to phosphorescence quenching (PO2is, in contracting muscle) and intravital microscopy (resting) measurements in the spinotrapezius muscle. Intravital microscopy revealed higher fRBC (70 & PLUSMN; 9 vs 25 & PLUSMN; 8 RBC/s), VRBC (490 & PLUSMN; 43 vs 226 & PLUSMN; 35 mu m/s), Hctcap (16 & PLUSMN; 1 vs 10 & PLUSMN; 1%) and a greater number of capillaries supporting flow (91 & PLUSMN; 3 vs 82 & PLUSMN; 3%) in HFrEF + BAY vs HFrEF (all P < 0.05). Additionally, PO2is was especially higher during 12-34s of contractions in HFrEF + BAY vs HFrEF (P < 0.05). Our findings suggest that sGC activators improved resting QO2 via increased fRBC, VRBC, and Hctcap allowing for better QO2-to-VO2 matching during the rest-contraction transient, supporting sGC activators as a potential therapeutic to target skeletal muscle vasomotor dysfunction in HFrEF.

Automated summary

In heart failure with reduced ejection fraction, dysfunction of the sGC pathway impairs skeletal muscle arteriolar vasodilation and oxygen uptake. The use of sGC activators improves blood flow dynamics and oxygen uptake, providing a potential therapeutic approach for HFrEF.